Search results for "CHOD"

showing 10 items of 372 documents

Między Starą a Nową Ojczyzną – muzyczna aktywność cymbalistów na Dolnym Śląsku w latach 50. XX wieku

2022

W artykule omówiono zagadnienie muzycznej aktywności cymbalistów, którzy zmuszeni byli do migracji z przedwojennych kresów wschodnich (Wileńszczyzny, Galicji Wschodniej) na Dolny Śląsk po II wojnie światowej. Będąc nowymi osadnikami na tzw. Ziemiach Odzyskanych, otoczeni ludnością o różnym pochodzeniu regionalnym, cymbaliści próbowali w nowych warunkach kontynuować muzyczną działalność. W tekście ukazane są różne sposoby adaptacji do nowej sytuacji wykonawczej w nowym miejscu zamieszkania: budowanie kolejnych instrumentów, granie w kapelach ludowych składających się z członków o różnym pochodzeniu regionalnym, próby indywidualnego muzykowania oparte na wykonywaniu muzyki tanecznej z regionu…

Lower Silesianagrania archiwalneDolny Śląskeastern borderlandsdulcimer playersmigrationcymbaliściarchival recordingskresy wschodniemigracjaRoczniki Humanistyczne
researchProduct

Inhalation solutions — Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers — Update 2013

2014

AbstractMany patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in vitro studies and a thorough literature search.Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients contained in some of the tested drug products could be identified as a reason for i…

Lung DiseasesPulmonary and Respiratory MedicineDrugmedicine.medical_specialtymedia_common.quotation_subjectReviewCompatibilityAdministration InhalationmedicineMixtureHumansPediatrics Perinatology and Child HealthClinical efficacyIntensive care medicineAerosolmedia_commonInhalationbusiness.industryNebulizers and VaporizersDornase alfaAnti-Bacterial AgentsBronchodilator AgentsChemical compatibilityDrug CombinationsNebulizerNebulizer solution/suspensionAnesthesiaChronic DiseasePediatrics Perinatology and Child Healthbusinessmedicine.drugJournal of Cystic Fibrosis
researchProduct

Inhaled Surfactant in the treatment of accidental Talc Powder inhalation: a new case report

2011

Abstract The use of talcum powder is incorrectly part of the traditional care of infants. Its acute aspiration is a very dangerous condition in childhood. Although the use of baby powder has been discouraged from many authors and the reports of its accidental inhalation have been ever more rare, sometimes new cases with several fatalities have been reported. We report on a patient in which accidental inhalation of baby powder induced severe respiratory difficulties. We also point out the benefits of surfactant administration. Surfactant contributed to the rapid improvement of the medical and radiological condition, preventing severe early and late complications and avoiding invasive approac…

Lung Diseasesmedicine.medical_specialtymedicine.medical_treatmentTreatment outcomeCase Reportmacromolecular substancesTalcSettore MED/38 - Pediatria Generale E SpecialisticaPulmonary surfactantAdministration InhalationSurfactantmedicineHumansTalcum powderRespiratory physiotherapyIntensive care medicinePhospholipidsBiological ProductsInhalationRespiratory distressbusiness.industrylcsh:RJ1-570InfantRespiratory Physiotherapylcsh:PediatricsPulmonary SurfactantsBronchopulmonary LavageAccidental InhalationAnti-Bacterial AgentsBronchodilator AgentsRadiographyTreatment OutcomeCoughBaby powderTalcRespiratory DistressAccidentalDrug Therapy CombinationFemaleInhaled surfactant talc powder inhalationPowdersbusinessmedicine.drugItalian Journal of Pediatrics
researchProduct

Global distributions of diazotrophs Gamma-A nifH genes abundance - Depth integrated values computed from a collection of source datasets - Contributi…

2013

The MAREDAT atlas covers 11 types of plankton, ranging in size from bacteria to jellyfish. Together, these plankton groups determine the health and productivity of the global ocean and play a vital role in the global carbon cycle. Working within a uniform and consistent spatial and depth grid (map) of the global ocean, the researchers compiled thousands and tens of thousands of data points to identify regions of plankton abundance and scarcity as well as areas of data abundance and scarcity. At many of the grid points, the MAREDAT team accomplished the difficult conversion from abundance (numbers of organisms) to biomass (carbon mass of organisms). The MAREDAT atlas provides an unprecedente…

M60/5SalinityChlorophyll aDiazotrophs total biomass as carbonUniform resource locator link to source data fileNitrateCTD/RosetteLatitude of eventNiskinM55 1Temperature waterCalothrix abundance expressed in number of nifH gene copiesratio expressed in mass of carbon per amount of nifH gene copiesCalculatedtop minUnicellular cyanobacteria-B biological trait ratio expressed in mass of carbon per amount of nifH gene copiesCD132biomass as carbonTrichodesmium biomass as carbonM55/1bottom maxCTD SeabirdTemperatureDepth top/minCTD RosetteSeabirdRichelia biological trait ratio expressed in mass of carbon per amount of nifH gene copiesCalothrixSO187 2Unicellular cyanobacteria-B abundance expressed in number of nifH gene copiesTrichodesmiumEarth System ResearchMARine Ecosystem Model Intercomparison Project MAREMIPDiazotrophsLongitude of eventRichelia associated speciesSample methodCalothrix biological trait ratio expressed in mass of carbon per amount of nifH gene copiesIronBottle NiskinwaterIn situ pumpMARine Ecosystem Model Intercomparison Project (MAREMIP)Unicellular cyanobacteria-C abundance expressed in number of nifH gene copiesPhosphateWater sampleSample commentUnicellular cyanobacteria biomassUniform resource locator/link to source data filetotal biomass as carbonHeterocyst biomassUnicellular cyanobacteriaProteobacteriaDate/Time of eventMeteor 1986Richelia abundance expressed in number of nifH gene copiesUnicellular cyanobacteria CUnicellular cyanobacteria Bbiological traitSO187/2RicheliaUnicellular cyanobacteria ADEPTH waterbiomassTrichodesmium abundance expressed in number of nifH gene copiesMeteor (1986)BottleDepthEvent labelDate Time of eventTrichodesmium biological trait ratio expressed in mass of carbon per amount of nifH gene copiesUnicellular cyanobacteria-C biological trait ratio expressed in mass of carbon per amount of nifH gene copiesMeasured at sea surfaceCTDCalothrix associated speciesCharles DarwinSonneabundance expressed in number of nifH gene copiesM60 5Depth bottom/maxUnicellular cyanobacteria-A abundance expressed in number of nifH gene copiesassociated speciesProteobacteria abundance expressed in number of nifH gene copiesHeterocyst
researchProduct

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Background: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect. Methods: Human sputum and blood neutrophils were isolated from healthy individuals ( n = 37), patients with stable COPD ( n = 52) and th…

Male0301 basic medicineNeutrophilsVesicular Acetylcholine Transport ProteinsAnti-Inflammatory AgentsDrug ResistanceNon-neuronal cholinergic systemPulmonary Disease Chronic Obstructive0302 clinical medicineMuscarinic acetylcholine receptorCOPDDrug SynergismAclidinium bromideMuscarinic acetylcholine receptor M2Middle AgedReceptors MuscarinicBronchodilator AgentsCorticosteroidDrug Therapy CombinationFemaleInflammation Mediatorsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyCombination therapymedicine.drug_classCorticosteroid resistanceMuscarinic AntagonistsFluticasone propionateCholine O-Acetyltransferase03 medical and health sciencesAclidinium bromideInternal medicinemedicineHumansCOPDAgedDose-Response Relationship Drugbusiness.industryResearchSputumMuscarinic antagonistmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemCase-Control StudiesFluticasonebusinessTropanesRespiratory Research
researchProduct

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct

First description of the male of Phlebotomus betisi Lewis and Wharton, 1963 (Diptera: Psychodidae).

2008

The male of Phlebotomus (Larroussius) betisi is described from Malayan caves. Several males have been caught in association with P. betisi females. Males and females have been associated by ecology, biogeography, morphology and molecular biology (homology of the ND4 mtDNA sequences).

MaleBiogeographyMolecular Sequence DataZoologyBiologyDNA MitochondrialPolymerase Chain ReactionCaveSpecies Specificityparasitic diseasesAnimalsPsychodidaegeographySex Characteristicsgeography.geographical_feature_categoryPhlebotomus betisiMalaysiaNADH Dehydrogenasebiology.organism_classificationInsect VectorsInfectious DiseasesPhlebotomusInsect ProteinsParasitologyTaxonomy (biology)FemaleSequence AlignmentParasitology international
researchProduct

Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controll…

2006

To evaluate the efficacy and tolerability of a novel hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) formulation of budesonide (Pulmicort) versus the conventional chlorofluorocarbon (CFC) pMDI formulation in paediatric patients with asthma.This was a Phase III, multicentre, 12-week, double-blind, randomised, parallel-group study involving children (6-12 years of age) with mild to moderate asthma. Patients received either budesonide HFA pMDI or budesonide CFC pMDI 200 mug twice daily, with or without a spacer (NebuChamber/Nebunette). Primary efficacy endpoint: mean percentage change in forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Secondary efficacy …

MaleBudesonideVital capacityHydrocarbons FluorinatedPeak Expiratory Flow Ratelaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawmedicineHumansMetered Dose InhalersBudesonideChildAsthmaChlorofluorocarbonbusiness.industryInhalerGeneral Medicinemedicine.diseaseMetered-dose inhalerAsthmaBronchodilator AgentsTreatment OutcomeAerosol PropellantschemistryTolerabilityAnesthesiaFemaleChlorofluorocarbonsbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct